Literature DB >> 19748631

Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure.

Tao-Sheng Li1, Masayuki Kubo, Kazuhiro Ueda, Masanori Murakami, Akihito Mikamo, Kimikazu Hamano.   

Abstract

OBJECTIVE: The implantation of autologous bone marrow-derived cells has been used for the treatment of ischemic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with different clinical backgrounds.
METHODS: Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various surgical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by using an ischemic limb model in mice with severe combined immunodeficiency.
RESULTS: When compared with their control cohort, bone marrow cells from patients with advanced age, renal failure, or anemia had significantly less c-kit- and CD34-positive stem cells (P < .05) and showed significantly lower vascular endothelial growth factor production and colony-forming units in culture (P < .05). Furthermore, the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the implantation of bone marrow cells from their control cohorts (P < .05). However, the bone marrow cells from patients with diabetes and hypertension did not show significant impairment of angiogenic potency when compared with their control cohorts.
CONCLUSIONS: The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age, renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the treatment of ischemic diseases. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748631     DOI: 10.1016/j.jtcvs.2009.07.053

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  20 in total

1.  Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes.

Authors:  Ayman Samman Tahhan; Muhammad Hammadah; Mohamad Raad; Zakaria Almuwaqqat; Ayman Alkhoder; Pratik B Sandesara; Heval Mohamed-Kelli; Salim S Hayek; Jeong Hwan Kim; Wesley T O'Neal; Matthew L Topel; Aubrey J Grant; Nabil Sabbak; Robert E Heinl; Mohamad Mazen Gafeer; Malik Obideen; Belal Kaseer; Nasser Abdelhadi; Yi-An Ko; Chang Liu; Iraj Hesaroieh; Ernestine A Mahar; Viola Vaccarino; Edmund K Waller; Arshed A Quyyumi
Journal:  Circ Res       Date:  2018-03-07       Impact factor: 17.367

2.  Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting.

Authors:  Alp Can; Ahmet Tulga Ulus; Ozgur Cinar; Ferda Topal Celikkan; Erdal Simsek; Mesut Akyol; Ugur Canpolat; Murat Erturk; Fadil Kara; Osman Ilhan
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

Review 3.  Pathologic function and therapeutic potential of exosomes in cardiovascular disease.

Authors:  Shaina Ailawadi; Xiaohong Wang; Haitao Gu; Guo-Chang Fan
Journal:  Biochim Biophys Acta       Date:  2014-10-16

Review 4.  c-kit(+) cells: the tell-tale heart of cardiac regeneration?

Authors:  Patrizia Nigro; Gianluca Lorenzo Perrucci; Aoife Gowran; Marco Zanobini; Maurizio C Capogrossi; Giulio Pompilio
Journal:  Cell Mol Life Sci       Date:  2015-01-10       Impact factor: 9.261

Review 5.  Exosomes: Fundamental Biology and Roles in Cardiovascular Physiology.

Authors:  Ahmed Ibrahim; Eduardo Marbán
Journal:  Annu Rev Physiol       Date:  2015-11-30       Impact factor: 19.318

Review 6.  Autologous stem cells in neurology: is there a future?

Authors:  Johannes P J M de Munter; Erik C Wolters
Journal:  J Neural Transm (Vienna)       Date:  2012-11-23       Impact factor: 3.575

7.  Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap.

Authors:  Manuel Mazo; Miriam Araña; Beatriz Pelacho; Felipe Prosper
Journal:  Stem Cells Int       Date:  2012-01-22       Impact factor: 5.443

8.  Diabetic impairment of C-kit bone marrow stem cells involves the disorders of inflammatory factors, cell adhesion and extracellular matrix molecules.

Authors:  Tao-Sheng Li; Satoshi Ikeda; Masayuki Kubo; Mako Ohshima; Hiroshi Kurazumi; Yoshihiro Takemoto; Kazuhiro Ueda; Kimikazu Hamano
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

9.  The mobilization and recruitment of c-kit+ cells contribute to wound healing after surgery.

Authors:  Yoshihiro Takemoto; Tao-Sheng Li; Masayuki Kubo; Mako Ohshima; Hiroshi Kurazumi; Kazuhiro Ueda; Tadahiko Enoki; Tomoaki Murata; Kimikazu Hamano
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

10.  Cell based therapy in Parkinsonism.

Authors:  Johannes Pjm de Munter; Chongsik Lee; Erik Ch Wolters
Journal:  Transl Neurodegener       Date:  2013-06-04       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.